Connor, Clark & Lunn Investment Management (CC&L)
DFTX

Connor, Clark & Lunn Investment Management (CC&L)’s Definium Therapeutics DFTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Buy
+8,295
New +$205K ﹤0.01% 1449

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DFTX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 8,295 shares worth $390K. The stake represents ﹤0.01% of the portfolio and ranks #1449 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 8,295 shares of Definium Therapeutics worth $390K as of Q2 2026.
  • Definium Therapeutics was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1449 holding.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.